Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis
Study sponsor: Tarsus Pharmaceuticals, Inc. · TARS
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2021-05-04Actual
Enrollment · participants421Actual
Source updated2023-12-21Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.